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Abstract
 Most patients with advanced gastrointestinal stromal tumorsBackground:
(GIST) develop drug resistance to tyrosine kinase inhibitors (TKIs) within two
years of starting therapy, whereas most chronic myeloid leukemia (CML)
patients in chronic phase still exhibit disease control after a decade on therapy.
This article aims to explain this divergence in long term outcomes.
 By combining clinical and experimental observationsMethods and results:
with mathematical formulas we estimate that, in advanced GIST, the genetic
changes responsible for resistance are generally already present at disease
detection.
 This result has relevant clinical implications by providing supportConclusion:
for the exploration of combination therapies.
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Introduction
Gastrointestinal stromal tumors (GIST) are sarcomas arising in the 
muscle wall of the gastrointestinal tract. The majority of GISTs are 
driven by activating mutations in the receptor tyrosine kinases KIT 
or PDGFR-α, whose aberrant signaling induces uncontrolled pro-
liferation and decreased apoptosis1. Because of the small number of 
driving genetic mutations, GISTs represent a paradigm for kinase-
driven solid tumors, and offer one of the best models to shed light 
on fundamental questions about cancer, providing a critical under-
standing of more genomically complex solid tumors.
Tyrosine kinase inhibitors (TKIs), such as imatinib and sunitinib, 
block the aberrant activation of KIT, leading to major clini-
cal benefits of objective response and durable disease control. 
Imatinib represents the standard first-line therapy for this disease 
when it is surgically incurable. However, imatinib does not cure 
advanced GIST2. Moreover, while the large majority of patients 
treated with imatinib do not show signs of primary resistance (dis-
ease progression within the first six months of therapy), second-
ary resistance to imatinib emerges in at least half the patients after 
two years of therapy and in more than 80% of patients after seven 
years1,3,4.
Imatinib was originally introduced to treat chronic myeloid leu-
kemia (CML), because of its specificity for the TK domain in the 
bcr-abl translocation gene, which characterizes the disease. Imatinib 
represents the standard first-line therapy and has led to dramatic 
improvements in outcomes for CML patients in the chronic phase: 
at six years the estimated event-free survival is 83%, and an esti-
mated 93% of treated patients are free from progression5. Impor-
tantly, secondary resistance is far less frequent in CML5.
In this article we consider two fundamental, clinically relevant, but 
still unanswered questions: Why do patients with advanced GIST 
often relapse and does secondary resistance originate before or dur-
ing TKI treatment?
Materials and methods
In order to obtain estimates for the probability of at least one drug 
resistant GIST cell being present at the time the tumor reaches a 
given diameter, and before the introduction of the TKI, we used 
formula (5) in Tomasetti et al.6:
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This formula estimates the probability of having resistant mutants 
PR in a tumor of size M, (number of cells), and is derived by count-
ing the number of divisions required for the tumor to reach that size. 
It is assumed that, at each cell division, there is a small probability 
u that one of the daughter cells is hit by a mutation known to induce 
drug resistance. The parameter l and d are the birth and death rates 
for the cell population, while a and b are the probabilities for the 
cells’ mode’s of division. This mathematical result is based on stand-
ard assumptions and has been successfully used to predict the develop-
ment of acquired resistance to targeted epidermal growth factor receptor 
(EGFR) blockade in colorectal cancer7. In order to apply this formula 
we used parameter estimates available in the literature, as follows.
The somatic point mutation rate u can be estimated to be between 
10-9 and 10-8 per base per cell division8,9. There are many known 
point mutations causing resistance to imatinib10. To obtain a con-
servative bound, we assumed a value of 10 point mutations in our 
calculations, though the actual number could be higher11. Overall, 
the probability of a point mutation causing drug resistance in GIST 
should then be at least 10-8 per cell division. It has been estimated that 
10-9 cancer cells are present per cm3 of tumoral mass12. As our goal 
was to generate an unfavorable scenario to our hypothesis, and since 
stromal tissue and other types of cells may be present, we halved this 
amount. Long-term drug resistance requires secondary mutations to 
be present in cells that are long-lived or able to self-renew13. KIT 
is known to have anti-apoptotic activity, thus contributing to cell 
lifespan14. Alternatively, resistance could arise from mutations in 
rare cells possessing stem cell attributes. Interstitial cells of Cajal 
progenitors are a potential candidate15. Their frequency is estimated 
to be 6.2 × 10-3 of all cells16. To be conservative, we only considered 
the stem cell compartment and set all other parameters of the main 
formula (5) in Tomasetti et al.6 to zero.
Using these results and parameters values, we can derive the lower 
bound of Figure 1 for the probability of at least one drug resistant 
GIST cell being present at the time the tumor reaches a given diam-
eter, and before the introduction of the TKI. Because we selected 
parameters to generate an unfavorable scenario to our hypothesis, 
we expected the actual curve to be above the curve of Figure 1. The 
calculation and the figure were obtained using the freely available 
R software (version 2.15.3)17.
Results
We combined experimental data with our mathematical formulas6 
that recently have been successfully used to predict the develop-
ment of acquired resistance to targeted EGFR blockade in colorec-
tal cancer7. By so doing, we have obtained the relationship shown in 
Figure 1 between the tumor diameter at detection, and the probabil-
ity that the tumor already harbors a resistant mutant at that time (see 
Materials and methods for the derivation of Figure 1). For example, 
for GISTs with diameters of 2 and 6 cm we estimate this probability 
to be equal to 0.12 and 0.97, respectively.
We now bring these elements to bear in interpreting recent clini-
cal observations. The size of a GIST at presentation may vary 
between 1 and >40 cm in diameter1. For example, in a clinical trial 
(NCT00237185) of 147 patients with unresectable or metastatic 
GIST expressing KIT and treated with imatinib, 75% of the patients 
had a GIST whose diameter was larger than 7 cm at treatment18. 
Based on Figure 1, we would expect the large majority of these 
patients to have resistant mutant cells already present by the time of 
GIST detection and therefore to develop resistance during therapy. 
In fact, only about 20% of the patients in this clinical trial were still 
progression-free after five and a half years from the start of imatinib 
treatment18.
The combination of experimental and clinical data with our math-
ematical estimates implies then that secondary resistance in patients 
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with advanced GIST is to be expected and is due to the large size 
of the tumor at detection time. That is, mathematical estimates indi-
cate that mutations responsible for secondary resistance are already 
present before the start of the treatment in patients with large tumor 
sizes, a key factor in explaining the high relapse of advanced GIST 
patients to TKI.
Discussion
It has been recently suggested that secondary resistance may be the 
result of the treatment itself rather than pretreatment mutations4. It 
is worth considering this issue further. Secondary mutations are not 
usually found at detection using conventional Sanger sequencing 
techniques4. However, these techniques are not sensitive for rare 
events. Because imatinib has not yet selected for resistant mutants, 
they may remain extremely rare, and thus are likely missed by the 
assays used for mutation analysis. Thus, the fact that mutants are 
rarely found at detection does not contradict the possibility that the 
point mutations did occur before treatment. Using our mathemati-
cal formulas again4, we estimate that if resistance is present in a 
GIST of 2 cm in diameter, only approximately 1 out of 108 tumor 
cells will be drug resistant. Most importantly, while resistance may 
also originate during treatment, this does not exclude the fact that 
random point mutations can occur during the re-treatment phase 
at each cell division. We have shown that the estimated number of 
resistant mutants produced before the start of the treatment is suffi-
cient to explain the observed clinical data. This logic also holds for 
the development of tertiary resistant clones that emerge within, on 
average, six months of starting second-line therapy with sunitinib 
following failure of imatinib19. Thus, our calculations, while not 
addressing the problem of primary resistance, are able to explain 
secondary resistance in advanced GIST.
Our prediction that patients with smaller GISTs at detection will 
have a smaller probability of progression has been already supported 
by the clinical correlation of tumor size at presentation with 
improved outcomes on imatinib18. With sufficient data, it may also 
be possible to observe a relation between tumor diameter at detec-
tion and probability of resistance that is similar in shape to Figure 1, 
since a resistant clone originating before therapy should eventually 
grow to a detectable size. Lastly, in the future, with next-generation 
DNA sequencing techniques, it may become possible to detect the 
presence of secondary mutations that represent a very small frac-
tion of cells at initial presentation.
Our results, if confirmed, would have important clinical implica-
tions. A therapy using a combination of TKIs (for example by add-
ing a new agent with novel spectrum activity to imatinib) would 
select only for those cells which have been hit by two point muta-
tions, each causing resistance to one of the drugs. We estimate that 
such a probability is very small for realistic values of the GIST 
diameter (not considering cross resistance). Therefore, combination 
therapy could drastically reduce the development of drug resistance 
caused by point mutations. Also, earlier detection of GIST offers 
the potential to provide measurable improvements in outcome, as 
long as it can result in a sufficiently large reduction in the average 
diameter at detection.
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Figure 1. The estimated lower bound for the probability that mutant 
cells resistant to imatinib are already present in a gastrointestinal 
stromal tumor (GIST) at time of treatment, as a function of tumor 
diameter.
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